Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer

SP70 is a novel tumor biomarker in patients with nonsmall cell lung cancer (NSCLC). However, its role as a marker for predicting the response to chemotherapy for patients with advanced NSCLC has not been investigated. A total of 152 patients were enrolled. Serum SP70, carcinoembryonic antigen (CEA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingping, Zhang, Wei, Gu, Min, Ji, Yazhou, Yang, Lu, Cheng, Xiangjun, Xiao, Xuelian, Xu, Jian, Gu, Chunrong, Zhang, Jiexin, Zhang, Shichang, Chen, Dan, Pan, Shiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051171/
https://www.ncbi.nlm.nih.gov/pubmed/29767438
http://dx.doi.org/10.1002/cam4.1555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051171/
https://www.ncbi.nlm.nih.gov/pubmed/29767438
http://dx.doi.org/10.1002/cam4.1555

Ejemplares similares